On June 11, 2026, Alpha Tau Medical Ltd. announced it received FDA clearance to complete enrollment in the REGAIN Recurrent Glioblastoma Trial and to add two additional U.S. clinical sites. Early interim results from the trial demonstrated 100% local disease control. The company operates in the medical device industry, developing oncology treatments.
